Americans Want To Know About Hillary Clinton’s Health

Americans Want To Know About Hillary Clinton’s Health

Presidential candidate Hillary Clinton has what is known as ‘Decision Fatigue’, to the point of requiring the medication Provigil.

I had decision fatigue caused from chronic insomnia. It got so bad I left the practice of medicine, with me too being on Provigil to keep me awake.  I took it with an amphetamine-based medication, as pep pills, to function.

The problem with this medication was the pills had side effects, and when the side effects were worse than the problem, I had to stop the pep pills or risk death. Stopping was no easy matter, as my fatigue became worse on stopping the medication.

If Hillary Clinton has decision fatigue, that is symptomatic of an underlying illness for which the fatigue prevents her from functioning.

Provigil is indicated when fatigue interferes with daily functioning. At one point I could not drive, because I was falling asleep at the wheel, and this was on my pep pills. I was on both Provigil and Vyvanse when I had a syncopal episode (fainting) resulting in open multiple fractures of  my face and head injury.  The medications elevated my blood pressure.

I made the initial decision to leave medical practice and was never able to return because of decision fatigue.

You see, I put my patients’ health and my oath to do no harm before my need to make an income or to continue with my dream job. So shouldn’t Hillary put this country and Americans before her need for power and money?

If Hillary will be too tired to make decisions, who will make them for her? Should that person seek office? Decision fatigue affects more than one’s ability to make decisions, it also affects functional capacity, especially executive function.

Also, what medication side effects can we expect from Provigil? Is she on other pep pills? And what is the underlying illness causing Hillary’s decision fatigue?

Americans, and indeed other nationalities, need to be reassured that the person elected to the highest position is physically and mentally fit to make sound decisions.

What do you think? Please leave a comment below…


Related Article:

Clinton Emails Discuss Whether to Take Drug Used to Treat ‘Decision Fatigue’

Here is a video from an anti-BLM racist that I actually like:  What’s Wrong with Hillary’s Health? | StateOfDaniel  #BlackLivesMatter

Comment: Call For More Information On Age-Related Memory Loss

Comment: Call For More Information On Age-Related Memory Loss



Comment From Mary:

Please keep me updated on all this information. This information can help so many people I know.

Please send me all the lab tests and other tests so I can make these recommendations. So many people are so stressed they they are in early stages if Alsheimers. I thing it is party

Just memory lost due to age

Let me know what tests need to be taken to find out. Please also what you would suggest to those to keep their memory as long as possible.
Thank you for your knowledge and time. This is a very important to so many people.


This is great news and reason for hope that age does not cause Alzheimer’s disease. The authors state, Alzheimer’s is distinct from age related memory loss, which is reversible.  This is preliminary, and already successful screening therapies that reverse age related memory loss in  rodents found.

Keep in mind the only finding was a suggestion. In addition, the study was post-mortem, performed on brains thought to have age-related dementia.

Study found one of unknown number of proteins involved in age-related dementia. Good news is multiple potential therapeutic interventions.

Hippocampus is an important area for memory, learning, and even depression. Age related dementia is a disorder associated with dysfunction in a sub-region of the hippocampus also affected by Alzheimer’s disease.

Alzheimer’s causes loss of neurons in the entorhinal cortex (EC), a region of the brain that provides major input neuron pathways to the hippocampus. This input affects the sub-region of the hippocampus affected by age-related dementia, dentate gyrus

The above is a nice explanation for the similarity of symptoms —early memory loss.    This study is compelling evidence that not all loss of memory is Alzheimer’s disease.  Age-related memory loss localized to dysfunctions in the sub-region of the hippocampus, dentate gyrus is reversible.  Evidently, researchers identified many effective SCREENING therapeutic interventions in RODENTS for age related dementia one of them is RbAp48.

Caution : Questions Remain on How to apply this information clinically?

1. How to distinguish clinically between age-related memory loss and early Alzheimer’s disease in humans remains unclear?
The article did not perform functional MRIs on humans [as this was a post-mortem test tube and animal study]

Will Early Alzheimer’s and age-related memory loss have similar functional MRI patterns in the initial stages of Alzheimer’s?


Are protein abnormalities, such as  RbAp48, in age-related memory loss unique  to this type of memory loss?  Are these proteins produced in the dentate gyrus  associated with other  pathologies,  starting with  diseases noted post-mortem?

2. What are the toxicities of RbAp48? As this was a post-mortem study toxic effects on humans are unknown; however, what are the toxicities in rodents?  These proteins produce other effects, what are the toxic effects of these proteins?

Below is a copy of the Phases of Clinical Trials

Found at: – Clinical Trial Phases (There are some variations)

FAQ – Clinical Trial Phases

Question: What are clinical trial phases?

Clinical trials are conducted in a series of steps, called phases – each phase is designed to answer a separate research question.

  • Phase I: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
  • Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
  • Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
  • Phase IV: Studies are done after the drug or treatment has been marketed to gather information on the drug’s effect in various populations and any side effects associated with long-term use.

Additional Resource Information on clinical trials can be found at


This study appears to be a pre-clinical study. Preclinical studies are animal studies or test tube studies intended to show efficacy, toxicity, and pharmacokinetics using a wide range of dosages.

In addition, the article’s  discussion of clinical efficacy of RbAp48 in age related dementia suggested the introduction of new drugs aimed at age-related memory loss.

Please remember the underlying thesis for these drugs.   Look for  Toxicity and Pharmacokinetics of RbAp48 and other similar drugs to be used for age-related memory loss.

Pharmacokinetics are the effects on a living human body of a drug from the moment of ingestion to elimination of the drug. Hopefully, other studies will follow that shed light on toxicity and pharmacokinetics before RbAp48 is used on healthy human subjects.

{The findings of many drug studies are not accessible to the public partly because subscription fees, unreasonably high, prevent access. }

In summary, pre-clinical studies form the basis of Phase 1 studies, performed on Healthy volunteers.

This study will guide future studies and give hope that not all memory loss is Alzheimer’s disease– in other words, progression to severe disabilities and death are not inevitable.

Also, this study informs radiologists, neurologists, internists and other physicians to look more closely at regions of the hippocampus, in particular the dentate gyrus sub-region  and the entorhinal cortex region of the brain, in diagnosing memory loss.

There is hope for those with age-related memory loss.


Sources Mentioned:



2.  Hippocampus

3. – Clinical Trial Phases

4. FAQ: – What is is an easy-to-use Web site that provides regularly updated information about federally and privately supported clinical trials. You can find specific clinical trials for a wide range of diseases and conditions.
Each record provided in lists the following:
• Disease or condition and experimental treatments studied
• Title, description, and design of study
• Requirements for participation
• Locations where the study is available
• Contact information
• Links to relevant information at other health Web sites, such MedlinePlus and PubMed
Additional Resource Information on clinical trials can be found at
Related Questions: questions

FMS Global News


Study points to possible treatments and confirms distinction between memory loss due to aging and that of Alzheimer’s

From the News Desk of Jeanne Hambleton

Source Newsroom: Columbia University Medical Center

Newswise — NEW YORK, NY — A team of Columbia University Medical Center (CUMC) researchers, led by Nobel laureate Eric R. Kandel, MD, has found that deficiency of a protein called RbAp48 in the hippocampus is a significant contributor to age-related memory loss and that this form of memory loss is reversible.

The study, conducted in postmortem human brain cells and in mice, also offers the strongest causal evidence that age-related memory loss and Alzheimer’s disease are distinct conditions.

The findings were published today in the online edition of Science Translational Medicine.

“Our study provides compelling evidence that age-related memory loss is a syndrome in its own right, apart from Alzheimer’s. In…

View original post 2,393 more words

In Spite of Massive Settlements, Brain Injury Lawsuits Keep Coming

In Spite of Massive Settlements, Brain Injury Lawsuits Keep Coming.

Middle East to vaccinate 20 million children against polio

Polio in Middle East

Middle East to vaccinate 20 million children against polio
Experts warn that the virus, known for paralyzing children, may spread from Syria to Europe as refugees flee conflict

Polio Outbreak Raises New Concerns in Syria


Report of suspected polio cases in the Syrian Arab Republic

Disease outbreak news

19 October 2013 – On 17 October 2013, WHO received reports of a cluster of acute flaccid paralysis (AFP) cases in the Syrian Arab Republic. This cluster of ‘hot’ AFP was detected in early October 2013 in Deir Al Zour province and is currently being investigated. Initial results from the national polio laboratory in Damascus indicate that two of the cases could be positive for polio – final results are awaited from the regional reference laboratory of the Eastern Mediterranean Region of WHO. Wild poliovirus was last reported in Syria in 1999.

Viral illness, contagious, causes weakness and paralysis.
Viral illness, contagious, causes weakness and paralysis.

The Ministry of Health of the Syrian Arab Republic confirms that it is treating this event as a cluster of ‘hot’ AFP cases, pending final laboratory confirmation, and an urgent response is currently being planned across the country. Syria is considered at high-risk for polio and other vaccine-preventable diseases due to the current situation.

A surveillance alert has been issued for the region to actively search for additional potential cases. Supplementary immunization activities in neighbouring countries are currently being planned.

Full story:

immunization schedule birth to 18 years



Saudi Arabia: New Infections Raise Virus Cases to 136

Saudi Arabia: New Infections Raise Virus Cases to 136
Saudi Arabia has confirmed six new infections from the potentially fatal MERS virus, the World Health Organization reported Friday